Equity
€36.6m from €66.1m in 2008
Equity fell by 45% in 17 years.
DOCPHARMA
Lifetime
18 annual accounts with figures on one time axis, 26 filings since 2000peak €25.1m (2008)
-not published
lowest -€17.7m (2009)
€581,444▼ 51.8%
peak €66.1m (2008)
€36.6m▲ 1.6%
€13,685▲ 9.8%
peak 73.6 FTE (2009)
-not published
Board30 names since 2003all names
2 directorsTomasz Buczek and 1 other
Owners5 names in the annual accounts
100%Viatris GX
Documentsfilings and deeds
07-07-202624 days before the deadline
2025financial year
Result from €1.2m to €581,444Resignation: MatthewSalzmann (director) 10-12Resignation: Vincent Verschraegen (director) 10-07
Key points
from the 2025 annual accountsResult
€581,444 ▼ 51.8%
The result fell in 2025 from €1.2m to €581,444.
Payment terms
200 days to suppliers
DOCPHARMA pays its suppliers 81 days earlier than in 2024.
Checked score
88
Excellent
Financially stronger than 69% of large companies without a NACE code
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.3%● unchanged vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.3%● unchanged vs 03-2025
05-2025: 0.3%● unchanged vs 04-2025
06-2025: 0.3%● unchanged vs 05-2025
07-2025: 0.4%▲ +0.1 percentage points vs 06-2025highest value
08-2025: 0.3%▼ -0.1 percentage points vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026
07-2026: 0.3%● unchanged vs 06-2026
08-2026: 0.3%● unchanged vs 07-2026lowest value
09-2026: 0.3%● unchanged vs 08-2026lowest value
10-2026: 0.3%● unchanged vs 09-2026lowest value
11-2026: 0.3%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 3522.44
No main activity registered
lowers risk
Size: total assets €48.2m
Founded in 1999
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, large). It does better than 67% of them on solvency, 98% on liquidity, 60% on profitability and 52% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 513 companies had the same profile as DOCPHARMA has now. Each dot stands for 2 companies, two years later.
96.1%
were still trading
3.1%
stopped another way
0.8%
went bankrupt
That fits the bankruptcy probability of DOCPHARMA itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 513 companies, not a prediction for DOCPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €3,200,000 on 30-day terms is acceptable
Short-term debt is 0% of total assets. 24.2% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
24 days early
2024
34 days early
2023
34 days early
2022
20 days early
2021
24 days early
2020
18 days early
2019
22 days early
← before the deadline
after the deadline →
tick = median of all Belgian filings
The company filed its last 7 accounts on average 25 days before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 7 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- Viatris GX 100%score 92equity €27.9m (2025) · annual accounts 2025
- Viatris Inc. consolidatesannual accounts 2020
Shares in 1 company, AKTUAPHARMA
Board & ownershipRecent changes
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Permanent representative: Tom Renders · General meeting of 18-06-2026 · Gazette deed
Resignation: MatthewSalzmann (director)
Appointment: ArunNarayan (director) · General meeting of 25-11-2025 · Gazette deed
Resignation: Vincent Verschraegen (director)
Appointment: Tomasz Buczek (director) · General meeting of 24-06-2025 · Gazette deed
Resignation: Luis Birbuet (director)
Appointment: Matthew Salzmann (director) · Director discharge: Luis Birbuet · General meeting of 28-02-2024 · Gazette deed
Official details
Source: KBO- Status
- Active since 05-03-1999Normal situation
- Activity
- “Alle industriële,commerciële verrichtingen met betrekking tot de chemische,farmaceutische,dieetvoeding- en cosmeticaproducten;” (deed in Dutch)From the articles, 7 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.103.154.9881560 Hoeilaart, since 23-11-1999
- Financial year end
- 31 December
- Peppol
- Reachable since 20-11-2020
Annual accounts 2025
- €48.2m▲ 2.2%
- Filing
- Filed on 07-07-2026, 24 days before the end of the filing period
Insights on DOCPHARMA
DOCPHARMA has existed since 1999. Turnover fell from €25.1m in 2008 to €91,069 in 2012.
Viatris GX holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DOCPHARMA
- What is the company number of DOCPHARMA?
- The company number of DOCPHARMA is 0465.350.075. The VAT number is the same number with BE in front: BE 0465.350.075.
- Where is DOCPHARMA based?
- The registered office is at Terhulpsesteenweg 6, 1560 Hoeilaart.Company details
- What is the legal form of DOCPHARMA?
- DOCPHARMA is a private limited company (BV).
- When was DOCPHARMA founded?
- DOCPHARMA was founded on 05-03-1999.
- Is DOCPHARMA still active?
- Yes, DOCPHARMA is an active enterprise in the KBO register.
- What is the turnover of DOCPHARMA?
- The annual accounts for financial year 2025 state no turnover.Financials
- Is DOCPHARMA profitable?
- In financial year 2025, DOCPHARMA made a profit of €581,444.
- Where can I find the annual accounts of DOCPHARMA?
- DOCPHARMA filed 31 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DOCPHARMA due?
- DOCPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.